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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and other aryl hydrocarbon receptor (AhR) ligands suppress
17-estradiol (E)-induced responses in the rodent uterus and mammary tumors and in human breast cancer
cells. Treatment of ZR-75, T47D, and MCF-7 human breast cancer cells with TCDD induces proteasome-
dependent degradation of endogenous estrogen receptor  (ER). The proteasome inhibitors MG132, PSI, and
PSII inhibit the proteasome-dependent effects induced by TCDD, whereas the protease inhibitors EST, calpain
inhibitor II, and chloroquine do not affect this response. ER levels in the mouse uterus and breast cancer cells
were significantly lower after cotreatment with E plus TCDD than after treatment with E or TCDD alone, and
our results indicate that AhR-mediated inhibition of E-induced transactivation is mainly due to limiting levels
of ER in cells cotreated with E plus TCDD. TCDD alone or in combination with E increases formation of
ubiquitinated forms of ER, and both coimmunoprecipitation and mammalian two-hybrid assays demonstrate
that TCDD induces interaction of the AhR with ER in the presence or absence of E. In contrast, E does not
induce AhR-ER interactions. Thus, inhibitory AhR-ER cross talk is linked to a novel pathway for degra-
dation of ER in which TCDD initially induces formation of a nuclear AhR complex which coordinately
recruits ER and the proteasome complex, resulting in degradation of both receptors.
Estrogenic hormones induce their tissue-specific responses
through binding the estrogen receptor (ER), which is a ligand-
activated transcription factor and a member of the nuclear
receptor (NR) superfamily (3, 15). The two ER subtypes (ER
and ER) and other NRs exhibit modular structures contain-
ing N-terminal activation function 1 (AF1) and C-terminal
AF2, which also contains the ligand-binding domain, a DNA-
binding domain (DBD), and an adjacent hinge region. Most
early-stage mammary tumors are ER positive and are respon-
sive to endocrine therapies which target ER and/or E biosyn-
thesis (5, 13, 47). Selective ER modulators, such as tamoxifen,
are extensively used for treating early-stage breast cancer, and
the primary modes of action of selective ER modulators in-
volve competitive binding to the ER and subsequent inhibition
of one or more steps in ER-mediated transactivation. Several
studies show that there are important mechanistic differences
among antiestrogens, and this is consistent with their tissue-
specific ER antagonist-agonist activities (20, 52, 53). For ex-
ample, the “pure” antiestrogens ICI 164,384 and/or ICI
182,780 not only bind ER with high affinity but induce a rapid
proteasome-dependent degradation of the receptor, and this is
observed in breast cancer cells and human tumors (41, 52).
Rapid degradation of ER protein in cells or tumors treated
with ICI 164,384 or 182,780 may play an important role in the
antiestrogenic activity of these compounds.
Studies in this laboratory have investigated inhibition of ER
signaling through cross talk with the ligand-activated aryl hy-
drocarbon receptor (AhR) (reviewed in references 36 and 44),
and selective AhR modulators are highly effective inhibitors of
mammary tumor growth in rodent models (32, 44). The envi-
ronmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
is a potent AhR agonist, and treatment of hepatoma cells with
TCDD induces rapid proteasome-dependent degradation of
the AhR (7, 30, 35, 40). Similar results have been observed in
T47D and MCF-7 human breast cancer cells treated with
TCDD or selective AhR modulators, and this is also accom-
panied by proteasome-dependent degradation of ER (32,
54). This study further investigates the mechanisms of AhR-
mediated degradation of ER protein in breast cancer cells
and the contributions of this pathway to inhibitory AhR-ER
cross talk. In breast cancer cells, TCDD alone and in combi-
nation with E induces rapid degradation of ER, and AhR
interaction with ER in a mammalian two-hybrid assay is de-
pendent on TCDD but not E. Interactions of ligand-bound
AhR with ER are accompanied by enhanced formation of
ubiquitinated forms of ER, proteasome-dependent degrada-
tion of ER, and decreased E-induced transactivation. Thus,
ligand activation of the nuclear AhR coordinately recruits both
ER and proteasomes which degrade both receptors and
thereby enhance inhibitory AhR-ER cross talk in breast can-
cer cells.
MATERIALS AND METHODS
Chemicals, constructs, cells, and animals. TCDD was prepared in this labo-
ratory and shown to be 99% pure by gas chromatographic analysis. 17-
Estradiol (E), chloroquine, cycloheximide, cell culture chemicals, and media
were purchased from Sigma. Calpain inhibitor II (Cal II), EST, MG132, PSI,
PSII, bis-indolylmaleimide I, manumycin A, U0126, PP2, wortmannin, and
KT5720 were purchased from Calbiochem. Primary antibodies for human ER,
AhR, Sp1, CYP1A1, c-Fos, and ubiquitin proteins were purchased from Santa
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Cruz. Alexa Fluor 594 goat anti-rabbit was purchased from Molecular Probes.
Fluorescein isothiocyanate-conjugated goat anti-rabbit was purchased from
Zymed Laboratories. The rat c-Fos pSP65 expression vector was kindly provided
by Tom Curran (Roche Research Center), and the human phuAhR expression
vector was a kind gift from Christopher Bradfield (University of Wisconsin
School of Medicine). The pERE3 reporter construct containing three tandem
consensus ERE sites linked to a luciferase gene was created by cloning an
oligonucleotide containing this sequence into the BamHI-HindIII-cut pXP-2
plasmid (American Type Culture Collection, Manassas, Va.) 30 bp upstream
from a TATA box. The sequence of the ERE was GGTCACAGTGACC. The
ER-GAL4-AD and AhR-GAL4-DBD fusion proteins were constructed using
the mammalian Matchmaker two-hybrid kit (Clontech) pVP16 and pM fusion
vectors. The expression plasmids for ER with deletions of amino acids 1 to 178
(ERAF1), 185 to 252 (ERDBD), and 282 to 595 (ERAF2) were kindly
provided by Pierre Chambon (Institute de Genetique et Biologie Moleculaire et
Cellulaire). T47D, MCF-7, and ZR-75 human breast cancer cells were obtained
from the American Type Culture Collection and cultured as previously described
(54). B6C3F1 mice were obtained from Charles River Laboratories. The mice
were kept in a temperature-controlled conditioned room with a 14-h light and
10-h dark photocycle. Rodent chow and water was supplied ad libitum.
Protein isolation and Western analysis. Cells were seeded into 35-mm six-well
tissue culture plates in phenol red-free medium (Dulbecco’s modified Eagle’s
medium [DMEM] Ham F-12) containing 2.5% charcoal-stripped fetal bovine
serum (FBS). After 24 h, cells were treated and harvested at designated time
points and lysed in ice-cold lysis buffer (50 mM HEPES [pH 7.5], 500 mM NaCl,
10% [vol/vol] glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA) supple-
mented with protease inhibitor cocktail (Sigma). Equal amounts of protein from
each treatment group were boiled in 1 Laemmli buffer (50 mM Tris-HCl, 2%
sodium dodecyl sulfate [SDS], 0.1% bromphenol blue, 175 mM -mercapto-
ethenol), separated by SDS–10% polyacrylamide gel electrophoresis (SDS-
PAGE), and electrophoresed to polyvinylidene difluoride (PVDF) membrane.
Membranes were blocked in Blotto (5% milk, Tris-buffered saline [10 mM
Tris-HCl, pH 8.0, 150 mM NaCl], and 0.05% Tween 20) and probed with primary
antibodies ERG-20 (1:1,000), AhR N-19 (1:200), Sp1 PEP2 (1:5,000), CYP1A1
G-18 (1:1,000), and c-Fos H-125 (1:1,000). Following incubation with peroxidase-
conjugated secondary antibody, immunoglobulins were visualized using the ECL
detection system (NEN). Quantitation was performed using a Sharp JX-330
scanner and Zero-D Scanalytics software (Scanalytics Corp.). The human ER,
human phuAhR, and rat c-Fos pSP65 expression vectors were used to in vitro
translate standards for Western blotting using the TNT T7 quick-coupled tran-
scription/translation system (Promega). Human recombinant Sp1 protein (Pro-
mega) was added to the in vitro-translated mixtures as the Sp1 standard.
Transfection assays. ZR-75 cells were seeded onto 12-well plates at a concen-
tration of 2.75  105 cells per well in phenol red-free DMEM Ham F-12
supplemented with 2.5% charcoal-stripped FBS. After 18 h, cells were trans-
fected by the calcium phosphate method with 500 ng of pERE3 luciferase re-
porter plasmid and 250 ng of pCDNA3.1--gal (Invitrogen) as the control vector.
Cells were treated for 36 h and assayed for luciferase (Promega) and -galac-
tosidase (Tropix) activity in a Packard luminometer according to the manufac-
turer’s instructions. Protein-protein interactions between ER and AhR were
examined in ZR-75 cells by using the ER-GAL4-AD (vpER) and AhR-GAL4-
DBD (pmAhR) fusion constructs. ZR-75 cells were transfected by the calcium
phosphate method with 500 ng of 5XGAL-luciferase, 250 ng of pmAhR, 100 ng
of vpER, 250 ng of pCDNA3.1--gal as the control vector, or empty pM and pVP
vectors as DNA mass balance controls. Cells were treated for 36 h, harvested,
and assayed as described above. The effects of TCDD on proteasome-dependent
degradation of ER mutants were determined in T47D cells. Cells were seeded
onto 35-mm six-well culture plates at a concentration of 6  105 cells per well in
DMEM Ham F-12 without phenol red, supplemented with 2.5% charcoal-
stripped FBS. After 18 h, cells were transfected by the calcium phosphate
method with 500 ng of ERAF1, ERDBD, or ERAF2 expression plas-
mids. After a 12-h recovery period, cells were treated with dimethyl sulfoxide
(DMSO; control) or 10 nM TCDD for 6 h. Cells were collected for transfected
and endogenous ER protein analysis using Western blotting buffers as de-
scribed in “Protein isolation and Western analysis.” Fifty-microgram protein
aliquots were electrophoresed for each treatment and transfection group.
Nuclear extract preparation and EMSA. MCF-7 and ZR-75 cells were seeded
at a density of 5  106 cells/plate in 60-mm tissue culture plates using DMEM
Ham F-12 without phenol red, supplemented with 2.2 g of sodium bicarbonate/
liter and antibiotic-antimycotic solution, and 2.5% charcoal-stripped FBS, pH
7.4. After 24 h, cells were treated for 3 h with 10 nM E or 10 nM E plus 10 nM
TCDD following a 30-min pretreatment with DMSO, 10 M MG132, or 10 M
Cal II. Nuclear extracts were obtained using the NE-PER nuclear and cytoplas-
mic extraction kit (Pierce) according to the manufacturer’s instructions. Three
micrograms of nuclear protein from each treatment group was incubated for 10
min at 25°C with 500 ng of poly(dI-dC) in 30 l of HEGDK (25 mM HEPES,
1.5 mM EDTA, 10% glycerol, 1 mM DTT, 100 mM KCl) and 32P-end-labeled
ERE probe (5-GTC CAA AGT CAG GTC ACA GTG ACC TGA AAG
TT-3). ER D-12 antibody and normal mouse immunoglobulin G (IgG) were
used for supershift controls. Samples were electrophoresed on a 5% polyacryl-
amide gel at 120 V in 90 mM Tris, 90 mM borate, 2 mM EDTA (pH 8.0), dried,
and visualized by autoradiography.
Northern blot analysis. T47D cells were seeded into 100-mm tissue culture
plates and, after 24 h, cells were treated for 6 h with DMSO or 10 nM TCDD
following a 30-min pretreatment with DMSO, 10 M MG132, or 10 M PSI.
Thirty micrograms of total RNA from each treatment was loaded onto a 1.2%
agarose, 10% formaldehyde gel and electrophoresed in 1 morpholinepropane-
sulfonic acid (MOPS) buffer. Separated RNA was transferred to Zeta-Probe GT
(Bio-Rad) membrane by capillary action in 1 MOPS for 48 h, UV cross-linked
for 15 min, dried at 80°C for 1 h, and probed at 42 to 65°C according to the
Zeta-Probe GT protocol. Membranes were scanned on a STORM 860 Phosphor-
Imager (Molecular Dynamics). Band intensities of AhR, Arnt, and ER were
normalized to values obtained for the -tubulin loading control. Expression
vectors used for generating RNA probes for Northern blot analysis were gener-
ously supplied by the following: AhR (Kristy Dolwick, Northwestern University
Medical School), Arnt (Rosally Agbunag, University of California), hER
(Ming-Jer Tsai, Baylor College of Medicine), and -tubulin (Masahito Negishi,
National Institute of Environmental Health Sciences, National Institutes of
Health).
Kinase inhibitors and cycloheximide studies. ZR-75 cells were seeded as
described in the Western immunoblotting protocol above and treated for 3 h with
DMSO, E, TCDD, or ET following a 30-min pretreatment with DMSO, 10 M
PP2, 1 M bis-indolylmaleimide I, 1 M KT5720, 2 M manumycin A, 5 M
U0126, 400 nM wortmannin, methanol (MeOH), or 25 M cycloheximide. Cells
were harvested and immunoblotted as described above in the “Protein isolation
and Western analysis” protocol.
Coimmunoprecipitation. MCF-7 and ZR-75 cells were seeded into 150-mm
tissue culture plates in maintenance medium and allowed to grow to approxi-
mately 90% confluence. Cells were treated with DMSO or 10 nM TCDD for 30
min, and nuclear extracts for each treatment group were obtained using the
NE-PER nuclear and cytoplasmic extraction kit with the addition of protease
inhibitor cocktail. Duplicate aliquots of 550 g (MCF-7) and 525 g (ZR-75) of
equal volume were used for the experiments. The nuclear protein was diluted
fivefold in ice-cold phosphate-buffered saline (PBS) containing protease inhibi-
tor cocktail to a final volume of 1 ml, followed by the addition of 30 l of protein
A/G PLUS-agarose beads (Santa Cruz). The reactions were placed on a rocker
at 4°C for 3 h, followed by centrifugation at 600  g at 4°C for 5 min. A 900-l
aliquot of supernatant was removed from each sample and placed into a new
Eppitube on ice. Mouse monoclonal anti-ERD-12 (1 g) or normal mouse IgG
(1 g) was added to either replicate treatment set, followed by the addition of 30
l of protein A/G PLUS-agarose beads. The samples were then placed on a
rocker at 4°C for 12 h, followed by centrifugation at 600 g at 4°C for 5 min. The
supernatant was removed by aspiration, and the pellets were washed once with
1 ml of ice-cold PBS followed by centrifugation at 600  g at 4°C for 5 min. The
agarose pellet was then resuspended in 50 l of 1 Laemmli buffer, boiled, and
centrifuged. The supernatant was separated by SDS–10% PAGE, electropho-
resed to PVDF membrane, and visualized by ECL as described above.
Ubiquitinated ER immunoprecipitation. ZR-75 cells were seeded as de-
scribed in the coimmunoprecipitation protocol above and treated with DMSO or
10 nM E, 10 nM TCDD or ET, or 10 nM ICI 182,780 for 6 h. Duplicate aliquots
of 300 g were immunoprecipitated with anti-Sp1 PEP2 (1 g) or anti-ERD-12
(1 g) as described above. Immunoprecipitates were washed with two cycles of
1 ml of ice-cold radioimmunoprecipitation assay buffer followed by 1 ml of
ice-cold PBS using centrifugation at 600  g at 4°C for 5 min. The agarose pellet
was resuspended in 50 l of 1 Laemmli buffer, boiled, and centrifuged, The
supernatant was separated by SDS–10% PAGE, electrophoresed to PVDF mem-
brane, blotted with anti-ubiquitin P4D1 (Sigma), and visualized by ECL as
described above. The membrane was then stripped using stripping buffer (62.5
mM Tris-HCl, 112 mM 2-mercaptoethanol, 20% SDS [wt/vol]; pH 6.8) at 60°C
for 1 h and reprobed with anti-ER  D-12 and anti-Sp1 PEP2 consecutively.
Effects of siRNA for the AhR. ZR-75 cells were cultured in DMEM Ham F-12
containing 5% FBS in six-well plates until 50 to 60% confluent. Based on results
of ongoing studies, a maximal decrease in the AhR protein was observed using
7 l of a 20 M solution of the small inhibitory RNA (siRNA), and this amount
was transfected into ZR-75 cells using oligofectamine reagent (Invitrogen, Carls-
bad, Calif.). The final concentration of siRNAs in each well was 140 nM. Thirty-
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six hours after transfection, cells were treated with DMSO, 10 nM E2, or 10 nM
TCDD for 5 h, and nuclear extracts were obtained and analyzed by Western blot
analysis for AhR, ER, and Sp1 proteins essentially as described elsewhere (1).
Replicate (three) experiments were carried out to quantitate the effects of
siRNA for the AhR on TCDD-induced downregulation of ER. The siRNA
oligonucleotides for the AhR and scrambled siRNA were as follows: scramble
siRNA, 5-GCG CGC UUU GUA GGA UUC G TT and TT CGC GCG AAA
CAU CCU AAG C-5; siRNA for AhR, 5-UAC UUC CAC CUC AGU UGG
C TT and TT AUG AAG GUG GAG UCA ACC G-5; siRNA for lamin A/C,
5-CUG GAC UUC CAG AAG AAC A TT and TT GAC CUG AAG GUC
UUC UUG U-5.
Immunofluorescence. For uterine immunohistochemistry, 25-day-old mice
were injected intraperitoneally with 200 ng of E in 100 l of corn oil, 1 g of
TCDD in 100 l of corn oil, ET, or corn oil alone. Twelve hours after treatment,
mice were euthanized by CO2 asphyxiation. Uteri were removed, fixed in 4%
paraformaldehyde overnight, washed with 70% ethanol, paraffin embedded, and
sectioned at a 5-m thickness onto positively charged slides and, after subse-
quent processing, slides were immunostained with ER H-184 antibodies and
analyzed by immunofluorescence as indicated below.
For immunocytochemistry, ZR-75 cells were seeded onto four-well glass
chamber slides at a density of 75,000 cells per well in RPMI maintenance
medium. After 24 h, cells were treated with DMSO, 10 nM E, 10 nM TCDD, or
ET for 24 h. Slides were then fixed for 10 min in 	20°C MeOH, air dried, and
washed for 5 min in PBS–0.3% Tween. Slides were blocked for 1 h with 5% goat
serum in antibody dilution buffer (1% bovine serum albumin–PBS–0.3%Tween–
31% glycerol [vol/vol] [pH to 8.0] with 0.5 M Na2CO3 [pH 9.5]). A 1:100 dilution
of anti-ER H-184–5% goat serum–antibody dilution buffer, or 5% goat serum–
antibody dilution buffer alone (control) was added to the samples and placed in
a humidified chamber overnight at 4°C. Slides were then washed three times for
30 min in PBS-Tween and blocked again for 1 h with 5% goat serum–antibody
dilution buffer. Alexa Fluor 594 goat anti-rabbit secondary antibody was added
at a 1:1,000 dilution in 5% goat serum–antibody dilution buffer to all samples for
1 h at room temperature. Slides were washed three times for 30 min in PBS-
Tween and once for 15 min in deionized water and mounted as above. Immu-
nofluorescence preparations were evaluated with a Zeiss Axioplan2 microscope
(Carl Zeiss) fitted with a Hamamatsu-C5810 chilled 3CCD color camera
(Hamamatsu Corporation). Images of at least three different fields from three
different sections per treatment group containing uterine luminal epithelium and
stromal cells were captured using identical settings. Fluorescence intensity mea-
surements of ER in both epithelial and stromal cells were obtained following
subtraction of background staining determined from the control prepared with-
out primary antibody. Values of mean fluorescence intensity 
 the standard
error (SE) were analyzed statistically.
Statistics. All quantitative data were analyzed by an analysis of variance
followed by Fisher’s protected least significant difference test for significance (P
 0.05). Data are expressed as means 
 SE (n  3).
RESULTS
TCDD induces proteasome-dependent degradation of ER
in breast cancer cell lines. ZR-75 human breast cancer cells
express ER and the AhR, and results in Fig. 1A summarize
the effects of treatment with DMSO (D), 10 nM TCDD (T),
and 10 nM E alone and in combination (ET) on levels of ER,
AhR, and Sp1 proteins in the presence of solvent (DMSO),
proteasome (MG132), or protease (Cal II) inhibitors. E in-
duced degradation of ER (but not AhR or Sp1), and this
response was inhibited by proteasome but not protease inhib-
itors. In cells treated with T or ET, there was coordinate
degradation of both ER and the AhR (but not Sp1) proteins
which was blocked by proteasome but not protease inhibitors.
Most significantly, there was a decrease in ER levels in all
three cell lines cotreated with ET compared to that of treat-
ment with E alone. The effects of the D, E, T, and ET treat-
ments are also illustrated in a time course study on ER
degradation in ZR-75 cells (Fig. 1B). There was a rapid and
sustained degradation of ER by TCDD and significantly
(50%) lower ER levels in cells treated with ET compared to
cells treated with E alone, and comparable results were ob-
tained in MCF-7 and T47D breast cancer cells. These data
complement results of previous studies in MCF-7 and T47D
cell lines, which also express AhR and ER proteins (54).
Thus, in three ER-positive breast cancer cell lines, TCDD
activation of AhR results in proteasome-dependent degrada-
tion of both AhR and ER proteins, whereas E induces deg-
radation of ER but not the AhR; cotreatment with ET en-
hanced ER degradation, whereas Sp1 levels were unchanged
in all treatment groups. The effects of TCDD and E on deg-
radation of ER mutants with deletions of the DBD
(ERDBD), AF1 (ERAF1), and AF2 (ERAF2) were
investigated by transient transfection in T47D cells (Fig. 1C).
TCDD- and E2-induced degradation of endogenous wild-type
ER served as a positive control. The results showed that in
cells treated with TCDD, deletion of the DBD did not affect
degradation, whereas deletion of AF1 or AF2 eliminated this
response. In contrast, E2 induced degradation of wild-type
ER, ERDBD, ERAF1, and ERAF2, showing that in
T47D cells, multiple domains of ER are targeted for degra-
dation by proteasomes. In contrast, degradation of ER in-
duced by TCDD was not observed for mutants with deletions
of AF1 or AF2, suggesting that TCDD and E2 induce distinct
patterns of ER degradation. A previous study showed that
E2-induced degradation of ER mutants by proteasomes in
HeLa cells was DBD dependent (52), indicating that cell con-
text is also important for ER degradation by proteasomes.
siRNAs can be used for gene silencing in mammalian cells (10,
16, 17), and studies in this laboratory have applied this tech-
nique for study of ER/Sp1 and AhR action in breast cancer
cells (1; M. Abdelrahim, unpublished results). Transfection of
ZR-75 cells with siRNA for the AhR inhibited TCDD-in-
duced, but not E2-induced, degradation of ER protein com-
pared to control (solvent-treated) cells or cells transfected with
scrambled siRNA (Fig. 1D and E). Sp1 was used as a control,
and levels of this protein were unaffected by any of the treat-
ments. Results illustrated in Fig. 1E show that siRNA for the
AhR induced degradation of the AhR but not Sp1 protein or
lamin A/C (data not shown), whereas siRNA for lamin A/C did
not affect AhR protein but decreased lamin A/C protein (data
not shown). Similar results were obtained in MCF-7 cells (data
not shown). Thus, AhR expression in ZR-75 cells is required
for TCDD-induced degradation of ER, and this has also been
previously observed in AhR-deficient MCF-7 cells (54).
The effects of E and ET treatment on binding of nuclear
extracts from MCF-7 cells to [32P]ERE were investigated in gel
mobility shift assays (Fig. 2A). Nuclear extracts from cells
treated with ET in solvent alone or in combination with Cal II
gave a retarded band with decreased intensity compared to the
band obtained using extracts from cells treated with E alone,
and these data corresponded to results of immunoblot analysis
of ER protein in the same extracts (Fig. 2B). In contrast, the
proteasome inhibitor MG132 blocked ER protein degrada-
tion in cells treated with E or ET, and nuclear extracts exhib-
ited increased retarded band intensities (compared to DMSO)
(Fig. 2A) and increased immunoreactive ER protein (Fig.
2B). Antibody supershift experiments with ER antibody or
nonspecific IgG confirmed that the retarded band complex
contained ER protein (Fig. 2A). The effects of the various
treatments on Sp1 protein were also determined as a control
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experiment, since levels of Sp1 are relatively constant in low-
passage breast cancer cells (54). The results (Fig. 2) show that
E, ET, and the proteasome and protease inhibitors did not
affect Sp1 protein expression, indicating specificity for the
AhR-ER interactions.
The effects of treatments on cellular ER levels were inves-
tigated by immunostaining ZR-75 cells with ER antibodies
(Fig. 3A). In cells treated with DMSO, there was widespread
staining of ER, which was located in the nuclei. Treatment of
the cells with 10 nM E, 10 nM T, or their combination for 24 h
caused a decrease in immunostaining of ER and, in the co-
treatment group, only low levels of nuclear ER were de-
tected. These results confirm that treatment of MCF-7 cells
with ET not only decreased immunoreactive ER protein but
also decreased binding of nuclear extracts to [32P]ERE, sug-
gesting that limiting levels of nuclear ER in cells treated with
ET may contribute to inhibition of E-induced gene and re-
porter gene expression by TCDD (reviewed in reference 44).
We also investigated the effects of E and ET in the immature
female mouse uterus, which is also responsive to inhibitory
AhR-ER cross talk (51). There was extensive swelling of
uterine epithelial and stromal cells after treatment with E for
12 h (Fig. 3B); however, in animals cotreated with ET, the
swelling response was decreased and expression of ER pro-
tein was lower in both stromal and epithelial cells. This re-
sponse in vivo paralleled the effects observed in ZR-75 cells.
Quantification of ER fluorescence intensity revealed that
treatment with E, T, or cotreatment with ET results in levels of
ER which are significantly lower than those observed after
treatment with corn oil alone (P  0.001). The mean ER
fluorescence intensity values obtained from uterine sections
were 56.41
 5.12, 30.26
 5.42, 27.88
 5.06, and 13.46
 3.48
for corn oil control, E, T, and ET, respectively.
Inhibitory AhR-ER cross talk: role of proteasome-depen-
dent degradation of ER. TCDD inhibits transactivation of
several E-induced genes in breast cancer cells (9, 14, 18, 21, 25,
38), and different mechanisms of inhibitory AhR-ER cross talk
have been proposed (36, 44). The results summarized in Fig.
4A show that E induces luciferase activity in ZR-75 cells trans-
fected with pERE3 alone and, in cells cotreated with E and
different concentrations of TCDD, there was a concentration-
FIG. 2. Decreased ER protein-DNA binding parallels diminished
ER protein levels. (A) Gel mobility shift assay. MCF-7 cells were
treated for 3 h with 10 nM E or 10 nM E plus 10 nM T (ET) following
a 30-min pretreatment with DMSO, 10 M MG132, or 10 M Cal II,
and binding of extracts to [32P]ERE was analyzed in a gel mobility shift
assay as described in Materials and Methods. Antibody supershift (SS)
experiments used ER antibody (D-12) or nonspecific mouse IgG. ns,
nonspecific binding. (B) Immunoreactive ER or Sp1 proteins in nu-
clear extracts. The same nuclear extracts from the treated cells from
panel A were also analyzed by Western blot analysis as described in
Materials and Methods. i.v., in vitro-translated ER and pure Sp1
protein control lane.
FIG. 1. Activated AhR causes degradation of ER in multiple breast cancer cell lines through the proteasome pathway. (A) ZR-75 cells were
treated for 3 h with DMSO (D), 10 nM E, 10 nM TCDD (T), or their combination (ET) following a 30-min pretreatment with vehicle control
(EtOH or DMSO), proteasome (MG132), or protease (Cal II) inhibitors at 10 M concentrations for each. Whole-cell extracts from the different
treatment groups were analyzed by Western blot analysis for ER (G-20), AhR (N-19), and Sp1 (PEP2) proteins as described in Materials and
Methods. Relative ER protein levels for each cell line are illustrated in bar graphs. (B) Time course degradation of ER in ZR-75 cells. Cells
were treated with DMSO, 10 nM E, 10 nM TCDD, or 10 nM ET for the designated times, and whole-cell extracts from the different treatment
groups (D, T, E, and ET) were analyzed for ER and Sp1 protein by Western blot analysis as described in Materials and Methods. In
vitro-translated ER, AhR, and pure Sp1 protein (i.v.) were used as controls. (C) Degradation of wild-type and variant ER in T47D cells. Cells
were transfected with ER variants treated with 10 nM E or 10 nM T, and levels of endogenous ER and transfected ER variants were
determined by Western blot analysis as described in Materials and Methods. Results are expressed as means 
 SE for three replicate determi-
nations, and levels of wild-type or variant ER significantly (P  0.05) lower than the controls (DMSO) are indicated with an asterisk. Western
blot analysis of these proteins is indicated (upper left). (D) Effects of siRNA for the AhR on degradation of ER. siRNA or scrambled siRNA
was transfected in ZR-75 cells and the effects of 10 nM TCDD or E2 on ER protein were determined by Western blot analysis of whole-cell
extracts as described in Materials and Methods. TCDD and E2 induced degradation of ER in control cells and cells transfected with scrambled
siRNA, whereas siRNA for AhR blocked the effects of TCDD but not E2. These data were observed in duplicate experiments. (E) Degradation
of ER and AhR. Cells were treated with DMSO, E, or T and siRNAs for the AhR or lamin A/C, and levels of ER/Sp1 (right) or AhR/Sp1 (left)
protein were determined in replicate (three) experiments. TCDD alone significantly (P  0.05) decreased levels of ER, and TCDD plus siRNA
for AhR (iAhR) significantly (P  0.05) reversed the effects of TCDD. siRNAs for the AhR (but not lamin A/C) significantly (P  0.05) decreased
AhR levels. Results are expressed as means 
 SE relative to control (DMSO) protein levels.
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dependent decrease in hormone-induced activity. In a parallel
experiment, treatment of ZR-75 cells with 10 nM E alone
decreased ER levels to 30% of those observed in control
(DMSO) cells (Fig. 4B), and this was associated with maximal
transactivation (Fig. 4A). These results are consistent with
previous reports and reflect the notion of spare ER levels
coupled with proteasome-dependent activation of ER (2, 11,
29, 49). However, in ZR-75 cells treated with E plus different
FIG. 3. AhR-mediated ER degradation occurs in situ. (A) ZR-75 cells were treated with DMSO (D), 10 nM E, 10 nM TCDD (T), or ET for
24 h, and ER was immunostained as described in Materials and Methods. Field width is 150 m. (B) Immature (25-day-old) B6C3F1 mice were
injected intraperitoneally with corn oil (C), 200 ng of E, or 1 g of TCDD (T) or ET for 12 h. Uteri were fixed and immunostained as described
in Materials and Methods. Field width is 240 m. Control fields represent background without ER H184 antibody.
FIG. 4. ER levels determine the magnitude of hormone-induced transactivation. (A) ZR-75 cells were transfected with pERE3 treated with
DMSO (D), 10 nM E, or E plus decreasing concentrations of TCDD (ET) for 36 h, and luciferase activity was determined as described in Materials
and Methods. Results are expressed as means for duplicate determinations for each treatment group. (B) In parallel duplicate experiments,
whole-cell extracts were collected, and ER protein levels in the various treatment groups described in the legend for panel A were analyzed by
Western blot analysis as described in Materials and Methods. i.v., in vitro-translated ER and pure Sp1 control lane. Results are expressed as
means for duplicate determinations for each treatment group. (C) TCDD cotreatment with E mediates a parallel decrease in ER protein and
transactivation. The data from panels A and B were used to plot the effects of increasing concentrations of TCDD on the percent decrease of ER
protein (F) and transactivation (E) below that observed in cells treated with E alone (set at 100%).
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concentrations of TCDD, there was a further decrease in ER
protein below levels observed in cells treated with E alone (Fig.
3B). Figure 4C illustrates the concentration-dependent effects
of TCDD on levels of ER protein as a percentage of ER
levels in cells treated with 10 nM E alone and on luciferase
activity as a percentage of the E-induced response. These par-
allel curves suggest that in the cells cotreated with ET, inhibi-
tion of E-induced transactivation by TCDD was related to the
enhanced AhR-mediated degradation of ER. These data sug-
gest that cotreatment with ET results in limiting levels of ER,
as observed in cells treated with the antiestrogen ICI 182,780,
which also induces proteasome-dependent degradation of
ER (41, 52). Previous studies have demonstrated that TCDD
inhibits induction of c-fos gene expression by E and induction
of E-responsive constructs containing c-fos gene promoter in-
serts, as shown in Fig. 4A for pERE3 (9). The results in Fig. 5A
demonstrate that TCDD also inhibits induction of c-Fos pro-
tein by E, and this was observed in the presence of a solvent
control (MeOH) or after addition of the protease inhibitor
EST. TCDD alone did not affect c-Fos protein levels. The
pattern of ER protein levels in these same treatment groups
(Fig. 5B) also showed that in cells treated with ET, both c-Fos
and ER protein levels were maximally decreased. The impor-
tance of ER protein levels in regulation of c-Fos was con-
firmed in cells treated with the proteasome inhibitor PSI,
where inhibition of E-induced c-Fos protein by TCDD was not
observed (Fig. 5A), and this correlated with high ER levels
which were maintained in the presence of PSI (Fig. 5B). In
contrast, levels of Sp1 protein were unaffected by the different
treatments (Fig. 5C). The results in Fig. 5A indicate that the
proteasome inhibitor PSI increases Fos protein levels in the
various treatment groups compared to levels observed in sol-
vent (MeOH) or protease-treated cells. These data suggest
that c-Fos protein is regulated by proteasomes in MCF-7 cells,
and this is consistent with the reported regulation of c-Fos
protein in other cells lines by the ubiquitin-proteasome path-
way (48, 50). Thus, inhibition of E-induced c-fos gene and
reporter gene expression by TCDD (9) is also accompanied by
decreased c-Fos protein levels, and these responses at the
protein (and gene) level correlated with the limiting ER lev-
els observed in breast cancer cells after cotreatment with ET.
Therefore, inhibitory AhR-ER cross talk in breast cancer
cells is dependent on ET-induced degradation of ER protein
by activation of proteasomes.
TCDD-induced ubiquitination of ER. Proteasome-depen-
dent degradation of proteins including ER is a multistep
process involving the 26S proteasome complex, in which pro-
teins targeted for degradation are first conjugated with ubiq-
uitin. Results illustrated in Fig. 6 summarize studies that in-
vestigated ubiquitination of ER in ZR-75 cells by using
immunoprecipitation and Western blot analysis of whole-cell
lysates or nuclear extracts from cells treated with solvent
(DMSO), 10 nM E, 10 nM TCDD or ET, or 10 nM ICI
182,780. Results of previous studies show that cells treated
with ICI 182,780 undergo a high level of ubiquitination and
protein degradation (52), and this treatment group served as a
positive control, whereas Sp1 protein levels are relatively con-
stant and served as an additional negative control protein for
FIG. 5. ER levels determine regulation of c-Fos protein expression. MCF-7 cells were pretreated for 30 min with methanol vehicle (MeOH),
10 M PSI, or 10 M EST. Cells were pretreated with T for 3 h prior to addition of 10 nM E (total DMSO did not exceed 0.03%), and c-Fos,
ER, and Sp1 proteins were detected by Western blot analysis from the same PVDF membrane, as described in Materials and Methods. i.v., in
vitro-translated rat c-Fos control. Results are expressed as means 
 SE for three determinations for each treatment group. Significant induction
of E-induced c-Fos protein is indicated by the letter a above the bar. Significant inhibition of E-induced c-Fos protein and decreased ER levels
by ET (compared to E) are indicated by the letter b above the bar (P  0.05).
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this study. Duplicate aliquots of nuclear extracts from different
treatment groups were immunoprecipitated with ER or Sp1
antibodies and then analyzed for ubiquitinated proteins by
Western blot analysis using ubiquitin antibodies (Fig. 6A). In
vitro-translated ER and human recombinant Sp1 protein and
15-g aliquots of nuclear extract served as controls for this
experiment. Minimal to nondetectable levels of ubiquitinated
proteins were detected in the lanes immunoprecipitated with
Sp1 antibodies. However, a series of ubiquitinated bands (84
kDa) were detected in the lanes immunoprecipitated with ER
antibodies, and increased staining of ubiquitinated bands was
observed in cells treated with E, TCDD, ET, and ICI 182,780
compared to DMSO (control). The in vitro and nuclear extract
control lanes show multiple ubiquitinated bands as expected,
given the propensity of this regulatory protein. The same
PVDF membrane was then stripped and reprobed with ER
antibodies (Fig. 6B). The results confirm that ER was immu-
noprecipitated, and the pattern of ER protein intensities was
comparable to those observed in the nuclear extracts. Higher-
molecular-weight bands are also visible in this panel, and some
of these may correspond to the ubiquitinated bands observed
in Fig. 6A. This same membrane was then reprobed with Sp1
antibodies (Fig. 6C), and Sp1 protein levels were similar in all
treatment groups; this was also observed in the nuclear extract
control. These data confirm that proteasome-dependent deg-
radation of ER induced by the ligand (TCDD)-activated
AhR gave enhanced ubiquitination of ER; moreover, the
higher-molecular-weight ubiquitinated ER bands are also ob-
served in cells after treatment with E or ICI 182,780.
AhR-mediated degradation of ER: modulation of gene ex-
pression, effects of protein synthesis, and kinase inhibitors.
Since TCDD activates proteasome-dependent degradation of
both AhR and ER protein, we also investigated the effects of
10 nM TCDD alone (DMSO) and in combination with pro-
FIG. 6. AhR-mediated ubiquitination of ER. ZR-75 cells were treated with DMSO (D), 10 nM E, 10 nM TCDD (T) or ET, or 10 nM ICI
182,780 for 6 h, and nuclear extracts (300-g aliquots) were immunoprecipitated with Sp1 (PEP2) or ER (D-12) antibodies. In vitro-translated
ER and pure Sp1 protein (i.v.) and 15 g of nuclear extract from each treatment group were loaded as controls. Western blot analysis was
performed as described in Materials and Methods. (A) The PVDF membrane probed with ubiquitin antibody (P4D1). (B) The same membrane,
stripped and reprobed with ER antibody (D-12). (C) The same membrane reprobed with Sp1 antibody (PEP2). Loading controls using heavy
chain, nonspecific, and light chain IgG are also shown.
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teasome inhibitors (MG132 and PSI) on ER, AhR, Arnt, and
-tubulin mRNA levels (Fig. 7A). The results show that ER
mRNA levels were similar in solvent control (D) or TCDD
(T)-treated in cells in the presence or absence of proteasome
inhibitors, and this was confirmed in four separate experi-
ments. Moreover, AhR, Arnt, and -tubulin mRNA levels
were also comparable in the different treatment groups, con-
firming that TCDD does not downregulate ER (or the AhR)
protein by decreasing mRNA levels. The role of protein syn-
thesis in activation of proteasomes by TCDD was investigated
in ZR-75 cells treated with solvent (D) or 10 nM TCDD (T)
alone (MeOH) or in the presence of 25 M cycloheximide
(Fig. 7B). The results show that TCDD induces degradation of
AhR and ER in the presence or absence of cycloheximide. In
contrast, cycloheximide inhibits induction of CYP1A1 protein
by TCDD, and this is consistent with previous studies on this
Ah-responsive gene in which TCDD induces both mRNA and
protein levels. These results suggest that activation of protea-
some-dependent degradation of AhR and ER by TCDD does
not involve new protein synthesis.
Activation of kinase pathways is required for proteasome-
dependent degradation of some proteins, and the results in
Fig. 7C summarize effects of several kinase inhibitors on ER
and Sp1 protein levels. Cells were treated with DMSO (D), 10
nM E, 10 nM TCDD or ET, and several inhibitors (kinases),
including 10 M PP2 (src), 1 M bis-indolylmaleimide 1 (pro-
tein kinase C), 1 M KT 5720 (protein kinase A), 2 M
manumycin A (ras), 5 M U0126 (mitogen-activated protein
kinase kinase [MAPKK]), or 400 nM wortmannin (phosphati-
dylinositol 3-kinase), for 3 h and whole-cell extracts were an-
alyzed for ER and Sp1 by Western blot analysis. The pattern
of downregulation of ER by TCDD was unaffected by the
kinase inhibitors, and similar effects were observed in cells
treated with E alone and ET, although the magnitude of the
response was decreased in cells cotreated with the ras inhibitor
manumycin A. The MAPKK inhibitor PD98059 blocked acti-
vation of proteasomes by TCDD (data not shown); however,
this compound and related 3-methoxy-substituted flavonoids
inhibit nuclear translocation and activation of the AhR by
TCDD (39), suggesting that this response is also required for
AhR-mediated activation of proteasomes.
Ligand activation of the AhR is required for AhR-ER in-
teractions. Klinge and coworkers (21) first showed that a glu-
tathione S-transferase (GST)-ER chimeric protein interacted
with the AhR (but not Arnt) in a pull-down assay, and this
interaction was AhR ligand (-naphthoflavone) dependent.
The results in Fig. 8 show that ER and AhR antibodies (but
not IgG) immunoprecipitated both the AhR and ER protein
in nuclear extracts from MCF-7 (Fig. 8A) or ZR-75 (Fig. 8B)
cells treated with 10 nM TCDD. There was also evidence for
some interactions of ER and the AhR in solvent (DMSO)-
treated ZR-75 cells; however, a more intense band was ob-
served in the extract from cells treated with TCDD. Interaction
of these proteins was further investigated in a mammalian
two-hybrid assay using an expression plasmid containing the
DBD of the yeast GAL4 protein (amino acids 1 to 147) fused
FIG. 7. Proteasome-dependent degradation of ER; role of mRNA levels, protein synthesis, and kinase inhibitors. (A) mRNA levels. T47D
cells were treated for 6 h with DMSO (D) or TCDD (T) following a 30-min pretreatment with DMSO, 10 M MG132, or 10 M PSI, and ER,
AhR, Arnt, and -tubulin mRNA levels were determined as described in Materials and Methods. (B) Effects of cycloheximide. ZR-75 cells were
treated for 3 h with DMSO (D) or 10 nM TCDD (T) following a 30-min pretreatment with MeOH or 25 M cycloheximide, and whole-cell lysates
were analyzed for AhR, ER, and CYP1A1 proteins by Western blot analysis as described in Materials and Methods. ns, nonspecific protein.
(C) Effects of kinase inhibitors. ZR-75 cells were treated with DMSO (D), 10 nM E, 10 nM TCDD (T), and ET for 3 h following a 30-min
pretreatment with 10 M PP2, 1 M bis-indolylmaleimide 1, 1 M KT5720, 2 M manumycin A, 5 M U0126, or 400 nM wortmannin. ER and
Sp1 proteins were determined by Western blot analysis as described in Materials and Methods.
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to full-length AhR (pm-AhR), and a plasmid expressing the
VP16 (amino acids 411 to 455) activation domain fused to
ER; empty vectors (pm and vp) served as controls. The
GAL4-responsive construct (pGAL4) contains five tandem
yeast GAL4 response elements linked to a luciferase reporter
gene. In cells treated with DMSO (solvent control) or E and
cotransfected with pmAhR plus vp (empty vector) or vpER,
comparable activities were observed, indicating that the high
activity was primarily due to unliganded pmAhR, and this was
not enhanced by vpER in the absence or presence of E. The
high basal activity of pmAhR in ZR-75 cells is in contrast to the
lower response observed for pmAhR (mouse) in COS cells,
which was similar to the activity of pm alone (19). This may be
due, in part, to breast cancer cell expression of cofactors such
as p300, steroid receptor coactivators, and TATA binding pro-
tein, which interact with the AhR (26, 33, 43). The activity of
pm-AhR plus vp was not increased in cells treated with TCDD
alone or ET; however, a significant increase (over pmAhR plus
vp) was observed when cells were cotransfected with pmAhR
plus vpER. Thus, ER-AhR interactions in the mammalian
two-hybrid assay were dependent on TCDD, and these results
were consistent with interactions of these proteins in the pull-
down assay (21). The pattern of vpER degradation in trans-
fected cells (Fig. 8D) was similar to that observed for wild-type
ER (Fig. 1). Previous studies showed that E induced degra-
dation of transfected vpER and ER in HeLa cells, and this
study confirms that TCDD alone or in combination with E also
induces degradation of both proteins in breast cancer cells.
Thus, TCDD-induced degradation of ER (and vpER) is
linked to physical interactions of AhR and ER.
DISCUSSION
The ubiquitin-proteasome pathway targets proteins for deg-
radation and plays a critical role in multiple biochemical pro-
cesses, including differentiation, cell cycle regulation, transport,
embryogenesis, immune responses, apoptosis, and control of
signal transduction (8, 12, 24, 34). Proteins targeted for deg-
radation by proteasomes are first ubiquitinated by enzyme-
catalyzed formation of polyubiquitin-protein conjugates, which
are substrates for ATP-dependent proteolysis by the 26S pro-
teasome complex. Proteasomes play an important role in reg-
ulating cellular expression of ER and other NR proteins;
however, there is considerable variability in proteasome acti-
vation and modulation of these nuclear transcription factors
(2, 4, 6, 11, 23, 27–29, 45, 46, 49, 55). For example, both the
androgen and vitamin D receptors are degraded by protea-
somes to maintain basal levels of these proteins, and receptor
agonists or proteasome inhibitors increase receptor levels
through inhibition of proteasome-dependent degradation in
FIG. 8. Activated AhR interacts with ER. MCF-7 (A) and ZR-75 (B) cells were treated with DMSO (D) or TCDD (T) for 30 min. Nuclear
extracts were isolated and immunoprecipitated with nonspecific mouse or goat IgG, anti-ER (D12), or the AhR. AhR and ER proteins were
analyzed by Western blot analysis as described in Materials and Methods. In vitro-translated AhR and ER were also used as markers.
(C) Mammalian two-hybrid interactions of pm-AhR and vp-ER in ZR-75 breast cancer cells. ZR-75 cells were transfected with pGAL4, pm plus
vp (empty vectors), pm plus vpER, pmAhR plus vp, or pmAhR plus vpER, treated with DMSO (D), 10 nM E (E), 10 nM (TCDD), or E plus
TCDD (ET), and luciferase activity was determined as described in Materials and Methods. Results are expressed as means 
 SE for three
separate determinations for each treatment group. Luciferase activity significantly (P  0.05) higher than that observed in cells transfected with
pmAhR plus vp is indicated with an asterisk. (D) Levels of vpER were also determined by Western blot analysis in cells transfected with pmAhR
and vpER. ns, nonspecific.
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several cell lines (28, 45, 46). In contrast, synthetic or endog-
enous ligands for the progesterone receptor, thyroid hormone
receptor, retinoic acid receptor (RAR), and ER activate pro-
teasome-dependent receptor degradation (4, 6, 23, 27, 28, 45,
46, 55).
Ligands for the AhR also activate proteasome-dependent
degradation of ER protein, and this process is not observed in
benzo(a)pyrene-resistant MCF-7 cells that do not express AhR
(54); AhR antagonists that inhibit formation of the nuclear
AhR complex also block AhR-mediated degradation of ER
(data not shown). siRNA oligonucleotides can be used for
gene silencing in mammalian cells (10, 16, 17), and this tech-
nique has been used for investigating ER/Sp1-mediated
transactivation and inhibitory AhR-ER cross talk in breast
cancer cells (1; M. Abdelrahim, unpublished results). Trans-
fection of siRNA for the AhR induces a 50 to 70% decrease in
AhR levels in MCF-7 cells and also inhibits degradation of
ER by TCDD but not E2 (Fig. 1D and E) These data com-
plement results of previous studies in AhR-deficient MCF-7
cells, where TCDD did not induce degradation of ER (54).
Results shown in Fig. 1 to 3 confirm that the AhR agonist
TCDD alone or in combination with E induces rapid degra-
dation of endogenous ER in at least three ER-positive
breast cancer cell lines (T47D, ZR-75, and MCF-7), and these
responses are blocked by proteasome inhibitors but not pro-
tease inhibitors. This represents a novel interaction between
ER and the basic helix-loop-helix AhR protein, in which
ligands for the AhR activate proteasome-dependent degrada-
tion of both AhR and ER, whereas ER agonists induce
proteolysis of ER but not the AhR. Interestingly, we also
observed a punctate pattern of nuclear ER staining in cells
treated with E, TCDD, and ET (Fig. 3A), and this has only
been observed in previous studies using ER-specific ligands
(49). The effects of ET in the mouse uterus (Fig. 3B) showed
that there was a significant decrease in E-induced swelling of
epithelial and stromal cells, and ET also decreased ER stain-
ing in epithelial and stromal cells. These responses in vivo
paralleled results in cell culture (Fig. 3A) and are consistent
with inhibitory AhR-ER cross talk previously observed in the
rodent uterus (42, 51).
This study investigates the mechanism and role of AhR-
dependent degradation of endogenous ER protein in medi-
ating inhibition of E-induced gene and reporter gene and pro-
tein expression in breast cancer cells. E activates degradation
of ER, and this is accompanied by high transactivation (Fig.
4) (29). Since both E and TCDD induce proteasome-depen-
dent degradation of ER, cells cotreated with ET express
20% of ER protein levels observed in untreated cells and
lower levels than in cells treated with E alone. Both ET and the
direct-acting pure antiestrogen ICI 182,780 induce substantial
degradation and ubiquitination of ER (Fig. 6), suggesting
that cellular levels of ER are limiting and are insufficient for
hormone-induced transactivation (Fig. 4 and 5). Thus, inhibi-
tory AhR-ER cross talk in these cells is linked to activation of
proteasome-dependent degradation of ER by ET.
Preliminary studies in this laboratory did not observe E- or
TCDD-induced degradation of transfected wild-type or mu-
tant ER in HeLa cells (data not shown). Moreover, our data
showed that E increased transfected ER levels, indicating
that transfected ER may behave differently from endogenous
FIG. 9. Proposed model for AhR-mediated degradation of ER through activation of the proteasome pathway. Cytosolic AhR is activated by
TCDD ligand, which induces disassociation of the heat shock protein 90 (hsp 90), AhR-interacting protein (AIP), and pp60Src kinase complex.
Activated AhR translocates to the nucleus, which enables direct interaction with nuclear ER, subsequent ubiquitination, and proteolysis by the
26S proteasome complex. Both ER ubiquitination and proteolysis are increased in cells cotreated with ET. E alone induces degradation of nuclear
ER but not the cytosolic AhR, and this may be due to lack of receptor colocalization.
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ER. Therefore, this study used E-responsive breast cancer
cell lines which express functional AhR and ER as models for
studying the mechanisms of AhR-dependent degradation of
ER through activation of proteasomes. Proteasome-depen-
dent degradation of ER is dependent on multiple factors,
including ligand structure, cell context, and the form of ER
expressed (i.e., wild type, chimeric, or mutant) (2, 11, 29, 52,
54). For example, one study reported that ligand-mediated
downregulation of ER is linked to coactivator recruitment
and coordinate degradation of both receptor and coactivator
proteins in HeLa cells transfected with ER or mutant ER
expression plasmids (29). In contrast, another study indicated
that mutations which block AF2-interacting coactivator re-
cruitment did not block proteasome-dependent degradation of
mutant ER or mutant chimeric vp-ER protein in HeLa cells
(52). Moreover, it was also reported that E2 did not induce
proteasome-dependent degradation of mutant ER containing
a DBD deletion in HeLa cells (52), whereas our results show
that TCDD- and E2-induced degradation of ER is DBD
independent and that the response for TCDD requires both
AF1 and AF2 of ER (Fig. 1C). These results clearly distin-
guish between activation of proteasomes by TCDD or E2
through their respective receptors, since different domains of
ER are required. These results also show that the effects of
E2 on degradation of ER are dependent on cell context (53).
Current studies are investigating specific regions within AF1
and AF2 of ER which are required for AhR-dependent deg-
radation of ER by proteasomes.
TCDD induces kinase activities in some tissues and cells
(31); however, results of ongoing studies indicate that TCDD
does not activate the src-MAPKK or –phosphatidylinositol
3-kinase pathways in ER-positive breast cancer cells (data not
shown). Therefore, the results in Fig. 7 showing that a series of
kinase inhibitors did not affect AhR-mediated degradation of
ER suggest that activation of kinase-dependent phosphory-
lation of ER by TCDD is not required for degradation of
ER by proteasomes. In contrast, MAPK-dependent phos-
phorylation of S294 of the progesterone receptor is required
for proteasome degradation of this receptor in T47D cells (27),
whereas RAR1 degradation by proteasomes is inhibited by
phosphorylation (23).
The AhR and ER can be coimmunoprecipitated in both
MCF-7 and ZR-75 cells (Fig. 8), and this interaction was en-
hanced by TCDD, suggesting a possible mechanism of AhR-
induced degradation of ER that involves initial ligand
(TCDD)-dependent interaction of AhR with ER. These in-
teractions were further investigated in a mammalian two-hy-
brid assay using pmAhR [GAL4(DBD)-AhR fusion protein]
and vpER (VP16-ER fusion protein) and treated with sol-
vent (D), E, or TCDD alone or in combination. Interactions of
AhR and ER were dependent on TCDD but not E. This was
similar to results of previous studies using GST-AhR and ER
in pull-down assays (21) and suggests an explanation for the
unidirectional ligand-dependent activation of proteasomes in
AhR-ER cross talk. E does not induce AhR-ER interac-
tions in the mammalian two-hybrid assay (Fig. 8) and, there-
fore, activates proteasome-dependent degradation of ER but
not the AhR (Fig. 1). Moreover, since the AhR and ER are
cytosolic and nuclear proteins, respectively, addition of E can-
not induce colocalization of both proteins in the nucleus. In
contrast, TCDD induces nuclear localization of the AhR,
AhR-ER interactions, and proteasome-dependent degrada-
tion of the receptors. These results suggest a mechanism (Fig.
9) in which ligand binding to AhR induces formation of the
nuclear AhR, which recruits both ER and proteasomes, re-
sulting in ubiquitination of AhR and ER and degradation of
both proteins. This process is highly specific, since Sp1 protein
is not affected by TCDD, even though Sp1 binds to both AhR
and ER (22, 37). Currently, we are using this model to further
investigate AhR-mediated degradation of specific domains of
ER and to determine the role of protein-protein interactions
in activating the proteasome pathway for degradation of one or
both interacting proteins.
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